#151352

Anti-CD19 [PDR134]

Cat. #151352

Anti-CD19 [PDR134]

Cat. #: 151352

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: CD19

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Karen Pulford

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CD19 [PDR134]
  • Alternate name: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
  • Clone: PDR134
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin’s lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
  • Immunogen: Pokeweek-stimulated Daudi and Raji cells
  • Isotype: IgM
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: CD19
  • Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin's lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Applications

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Sato S and Tedder TF. 1997. CD19 Workshop Panel report. In Kishimoto T, et al (eds) Leucocyte Typing VI, Garland Publishing Inc., New York and London, p 133-135
  • Tedder TF et al. 1995. B-cell antigens: section report. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 491.